Michael Gelband’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Michael Gelband’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-952,343	Closed	-$4M	–	2373
2023 Q1	$4M	Buy	952,343 +643,530	+208%	+$3.34M	0.03%	592
2022 Q4	$1.86M	Buy	+308,813	New	+$1.69M	0.03%	678
2022 Q2	–	Sell	-80,916	Closed	-$378K	–	2772
2022 Q1	$378K	Buy	+80,916	New	+$241K	﹤0.01%	1671
2021 Q2	–	Sell	-189,516	Closed	-$551K	–	3075
2021 Q1	$551K	Sell	189,516 -46,301	-20%	-$151K	0.01%	1278
2020 Q4	$759K	Buy	+235,817	New	+$784K	0.01%	1007

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Michael Gelband's CTIC Position: Q2 2023 in Review

Michael Gelband sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 952,343 shares — an estimated $4M sold.

Michael Gelband first reported a position in CTIC in Q4 2020 and held it in 5 quarters. The position peaked at $4M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Michael Gelband reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Michael Gelband sold 952,343 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4M.
Michael Gelband first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 5 quarters.
Michael Gelband's CTI BioPharma Corp. (DE) Common Stock position peaked at $4M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.